Continuous Renal Replacement Therapy Market – By Modality (Continuous Venovenous Hemofiltration, Continuous Venovenous Hemodiafiltration, Continuous Venovenous Hemodialysis, Slow Continuous Ultrafiltration), By Product (Instruments, Consumables), By Therapy, & Forecast, 2023 – 2032

Continuous Renal Replacement Therapy Market Size

Continuous Renal Replacement Therapy Market size was worth more than USD 1 billion in 2022 and is estimated to witness robust growth at 6.9% CAGR from 2023 to 2032 attributed to the rising incidences of chronic renal diseases. As per recent data from 2022, chronic kidney diseases (CKD) is projected to impact 9.1% to 13.4% of the global population.
 

The growing episodes of kidney disorders can be attributed to unhealthy lifestyles as well as the increasing prevalence of diabetes, hypertension, and other comorbidities. According to the CDC, 37.3 million Americans, or 11.3% of the population suffered from diabetes in 2022. Furthermore, the presence of rapidly expanding geriatric population base worldwide vulnerable to renal illnesses has surged the demand for CRRT treatments. Moreover, the rising demand for advanced CRRT equipment and procedures in clinical settings to offer higher effectiveness, safety, and convenience of use will add to the market expansion.  

The operational challenges associated with CRRT treatment methods may pose as a restraint for the market growth. To operate and manage the equipment efficiently, CRRT requires specialized training and technical knowledge. Increasing errors in machine setup, parameter modifications, or patient management leading to complications along with the shortage of qualified workers may also slow down the market growth.
 

COVID-19 Impact

The COVID-19 outbreak imposed unexpected challenges for patients with renal diseases and their care providers. The pandemic disrupted global supply chains, impacting the availability of medical equipment such as CRRT machines and consumables. However, it had favorable influence on the overall market. According to studies, more than 30% of COVID-19 hospitalized patients experienced renal injury, and more than 50% of patients in ICUs with kidney injury required dialysis. Nevertheless, the need to identify effective COVID-19 therapies stimulated medical research and innovation, adding to the market progression.
 

Continuous Renal Replacement Therapy Market Trends

The significant improvements in user interface, automation, and safety characteristics of continuous renal replacement treatment systems will have positive impact on the market growth. Touch-screen interfaces, automatic changes depending on patient characteristics, and safety alerts have become standard features in newer CRRT machines, making them easier to use while lowering the chances of treatment mistakes. Moreover, healthcare facilities are rapidly adopting these solutions as they make the preparation procedure easier, provide regular fluid balance during treatment, and lower the chance of mistakes when producing replacement fluids. For instance, in January 2023, Peconic Bay Medical Centre announced the launch of a new and advanced dialysis program, CRRT, to be offered to patients suffering from kidney damages.
 

Continuous Renal Replacement Therapy Market Analysis

Continuous renal replacement therapy market size from the continuous venovenous hemodialysis (CVVHD) is expected to reach USD 1 billion by 2032. CVVH is an effective and adaptable therapy for critically ill AKI (acute kidney injury) patients as it offers continuous renal support, offering more progressive and continuous filtration of patients' blood flow. It is useful for a wide spectrum of AKI patients due to its capacity to adjust therapy to specific patient demands. Widespread acceptability and significant adoption across critical care settings will fuel the segment expansion.
 

The consumables segment held significant continuous renal replacement therapy market share in 2022 and is estimated to witness considerable growth to reach around USD 1.3 billion by 2032. Hemofilters and dialyzers are critical CRRT consumables that filter waste products, excessive fluids, and electrolytes from the patient's blood flow. The widespread adoption of high-performance filters has increased the efficacy of CRRT, resulting in improved patient outcomes. Furthermore, the higher availability of government schemes and reimbursement rules will accelerate the segment growth. For instance, in India, the Pradhan Mantri National Dialysis Program provided dialysis services to a total of 17.27 lakh beneficiaries as of December 31, 2022.
 

North America continuous renal replacement therapy market size exceeded USD 371 million in 2022 and will record substantial growth through 2032 owing to the increasing demand for CRRT among the expanding senior population prone to renal failures. According to NIDDK estimates, the incidence of CKD in those aged 65 and more in the U.S. is 14%, meaning that approximately 1 in every 7 adults aged 65 and more have CKD. Furthermore, the rising per capita incomes and healthcare spending will have beneficial impact on the regional market outlook.
 

Continuous Renal Replacement Therapy Market Share

Some of the key players operating in the continuous renal replacement therapy market include

• Medtronic
• B.Braun Melsungen
• Asahi Kasei Corporation
• Baxter International Inc.
• Medica
• Medites
• Medical Components
• Nikkiso
• Nxtstage
• Toray
• Tricol Biomedical
   

Continuous Renal Replacement Therapy Industry News

• In May 2022, Baxter International Inc., announced that its ST Set for continuous renal replacement therapy (CRRT) received FDA 510(k) approval.
   
• In August 2022, Fresenius Medical Care North America's Renal Therapies Group launched Speedswap®, as a new option for the NxStage® System OneTM with NxViewTM to allow the replacement of a flow-compromised dialysis filter without replacing the complete cartridge.
   

Continuous renal replacement therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD (million) and volume (Units) from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Modality, 2018 - 2032 (USD Million)

• Continuous Venovenous Hemofiltration
• Continuous Venovenous Hemodiafiltration
• Continuous Venovenous Hemodialysis
• Slow Continuous Ultrafiltration

By Product, 2018 - 2032 (USD Million & Units)

• Instruments
• Consumables

By Therapy, 2018 - 2032 (USD Million)

• Renal
• Non-renal

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Switzerland
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Iran
  • Turkey